Inhibikase Therapeutics Past Earnings Performance
Past criteria checks 0/6
Inhibikase Therapeutics's earnings have been declining at an average annual rate of -31.2%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 36% per year.
Key information
-31.2%
Earnings growth rate
-0.8%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -36.0% |
| Return on equity | n/a |
| Net Margin | -1,956,524,900.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Inhibikase Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -20 | 7 | 0 |
| 30 Jun 24 | 0 | -18 | 7 | 0 |
| 31 Mar 24 | 0 | -19 | 7 | 0 |
| 31 Dec 23 | 0 | -19 | 7 | 0 |
| 30 Sep 23 | 0 | -19 | 7 | 0 |
| 30 Jun 23 | 0 | -19 | 7 | 0 |
| 31 Mar 23 | 0 | -18 | 6 | 0 |
| 31 Dec 22 | 0 | -18 | 6 | 0 |
| 30 Sep 22 | 0 | -19 | 7 | 0 |
| 30 Jun 22 | 0 | -19 | 7 | 0 |
| 31 Mar 22 | 2 | -17 | 7 | 0 |
| 31 Dec 21 | 3 | -15 | 7 | 0 |
| 30 Sep 21 | 3 | -11 | 6 | 0 |
| 30 Jun 21 | 3 | -7 | 5 | 0 |
| 31 Mar 21 | 2 | -5 | 4 | 0 |
| 31 Dec 20 | 1 | -3 | 3 | 0 |
| 30 Sep 20 | 1 | -2 | 2 | 0 |
| 30 Jun 20 | 1 | -3 | 2 | 0 |
| 31 Mar 20 | 1 | -5 | 4 | 0 |
| 31 Dec 19 | 1 | -6 | 4 | 0 |
| 30 Sep 19 | 2 | -7 | 5 | 0 |
| 31 Mar 19 | 4 | -4 | 3 | 0 |
| 31 Dec 18 | 4 | -2 | 3 | 0 |
| 30 Sep 18 | 3 | -1 | 2 | 0 |
| 31 Mar 18 | 3 | 0 | 1 | 0 |
| 31 Dec 17 | 2 | 0 | 1 | 0 |
| 31 Dec 16 | 1 | -1 | 1 | 0 |
Quality Earnings: IQT0 is currently unprofitable.
Growing Profit Margin: IQT0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IQT0 is unprofitable, and losses have increased over the past 5 years at a rate of 31.2% per year.
Accelerating Growth: Unable to compare IQT0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IQT0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: IQT0's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.